Floatz logo

Acoramidis

Amyloidosis in Transthyretin (TTR)

Eidos Therapeutics, a BridgeBio companySmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Amyloidosis in Transthyretin (TTR) cohort.

Asset / SponsorPhaseRating
Acoramidis
Bayer
Phase 4BBB
DEXAMETHASONE
Ascentage Pharma Group Inc.
Phase 3BB
Empagliflozin
Columbia University
Phase 4BB
fx-1006a
Pfizer
Phase 4BB
Cyclophosphamide
University of Alabama at Birmingham
Phase 2BB

View all 38 →

Same molecule, other indications

Acoramidis is also rated in:

amyloidosisDormant
BBB
Indicative ·
78 / 100
View asset →
Amyloid Cardiomyopathy, Transthyretin-RelatedDormant
BB
Indicative ·
66 / 100
View asset →
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Dormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →